Nepsis Inc. recently filed their 13F report for the fourth quarter of 2022, which ended on 2022-12-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
8674 Eagle Creek Circle Minneapolis, MN 55378
As of the latest 13F report, the guru’s equity portfolio contained 30 stocks valued at a total of $299.00Mil. The top holdings were DVN(8.38%), RNR(7.20%), and AIG(6.44%).
According to GuruFocus data, these were Nepsis Inc.’s top five trades of the quarter.
CVS Health Corp
The guru sold out of their 156,239-share investment in NYSE:CVS. Previously, the stock had a 5.39% weight in the equity portfolio. Shares traded for an average price of $96.48999999999999 during the quarter.
On 01/25/2023, CVS Health Corp traded for a price of $84.84 per share and a market cap of $111.48Bil. The stock has returned -15.16% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, CVS Health Corp has a price-earnings ratio of 36.10, a price-book ratio of 1.58, a price-earnings-to-growth (PEG) ratio of 6.94, a EV-to-Ebitda ratio of 15.25 and a price-sales ratio of 0.36.
The price-to-GF Value ratio is 0.91, earning the stock a GF Value rank of 6.
Jazz Pharmaceuticals PLC
The guru established a new position worth 82,606 shares in NAS:JAZZ, giving the stock a 4.41% weight in the equity portfolio. Shares traded for an average price of $146.56 during the quarter.
On 01/25/2023, Jazz Pharmaceuticals PLC traded for a price of $153.69 per share and a market cap of $9.68Bil. The stock has returned 16.58% over the past year.
GuruFocus gives the company a financial strength rating of 4 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Jazz Pharmaceuticals PLC has a price-book ratio of 3.52, a EV-to-Ebitda ratio of 16.71 and a price-sales ratio of 2.68.
The price-to-GF Value ratio is 0.85, earning the stock a GF Value rank of 7.
Everest Re Group Ltd
The guru established a new position worth 20,960 shares in NYSE:RE, giving the stock a 2.32% weight in the equity portfolio. Shares traded for an average price of $311.56 during the quarter.
On 01/25/2023, Everest Re Group Ltd traded for a price of $347.19 per share and a market cap of $13.60Bil. The stock has returned 23.13% over the past year.
GuruFocus gives the company a financial strength rating of 5 out of 10 and a profitability rating of 7 out of 10.
In terms of valuation, Everest Re Group Ltd has a price-earnings ratio of 26.01, a price-book ratio of 1.77, a EV-to-Ebitda ratio of 24.21 and a price-sales ratio of 1.15.
The price-to-GF Value ratio is 1.05, earning the stock a GF Value rank of 5.
FuboTV Inc
The guru sold out of their 1,573,286-share investment in NYSE:FUBO. Previously, the stock had a 2.02% weight in the equity portfolio. Shares traded for an average price of $3.05 during the quarter.
On 01/25/2023, FuboTV Inc traded for a price of $2.105 per share and a market cap of $411.16Mil. The stock has returned -78.44% over the past year.
GuruFocus gives the company a financial strength rating of 3 out of 10 and a profitability rating of 1 out of 10.
In terms of valuation, FuboTV Inc has a price-book ratio of 0.85, a EV-to-Ebitda ratio of -1.26 and a price-sales ratio of 0.40.
The price-to-GF Value ratio is 0.07, earning the stock a GF Value rank of 2.
F5 Inc
Nepsis Inc. reduced their investment in NAS:FFIV by 30,435 shares. The trade had a 1.59% impact on the equity portfolio. During the quarter, the stock traded for an average price of $146.39.
On 01/25/2023, F5 Inc traded for a price of $142.63 per share and a market cap of $8.61Bil. The stock has returned -34.88% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, F5 Inc has a price-earnings ratio of 26.96, a price-book ratio of 3.46, a EV-to-Ebitda ratio of 15.96 and a price-sales ratio of 3.22.
The price-to-GF Value ratio is 0.78, earning the stock a GF Value rank of 9.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
When GuruFocus covers insider information, we only track open market or the private purchase and sale of common stock with the transaction code of P or S. Therefore, all the transactions mentioned in this article are only the ones with transaction code of P or S.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
